FTP-637

Generic Name: FTP-637

Clinical Trials

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

Phase 1

Recruiting

Conditions: Renal Impairment

Interventions: Drug: ESK-001

First Posted Date: 2025-05-08

Last Posted Date: 2025-05-08

Lead Sponsor: Alumis Inc

Target Recruit Count: 48

Registration Number: NCT06962774

Locations: 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Floridian Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Advanced Pharma CR, Miami, Florida, United States

and more 1 locations

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

Phase 1

Recruiting

Conditions: Hepatic Impairment

Interventions: Drug: ESK-001

First Posted Date: 2025-05-01

Last Posted Date: 2025-05-01

Lead Sponsor: Alumis Inc

Target Recruit Count: 48

Registration Number: NCT06952634

Locations: 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

and more 1 locations

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

Phase 3

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: ESK-001
Drug: Placebo
Drug: Apremilast

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-25

Lead Sponsor: Alumis Inc

Target Recruit Count: 840

Registration Number: NCT06588738

Locations: 🇭🇺
Orvostudomanyi Kutato es Fejleszto Kft, Debrecen, Hungary
🇭🇺
Allergo Derm Bakos Kft, Szolnok, Hungary
🇭🇺
Medmare Bt, Veszprém, Hungary

and more 145 locations

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: ESK-001
Drug: Placebo
Drug: Apremilast

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-14

Lead Sponsor: Alumis Inc

Target Recruit Count: 840

Registration Number: NCT06586112

Locations: 🇺🇸
Alliance Dermatology, Phoenix, Arizona, United States
🇺🇸
Scottsdale Clinical Trials, Scottsdale, Arizona, United States
🇺🇸
Northwest Arkansas Clinical Trials Center (NWACTC), PLLC, Rogers, Arkansas, United States

and more 180 locations

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Phase 2

Recruiting

Conditions: SLE

Interventions: Drug: ESK-001
Drug: Placebo

First Posted Date: 2023-07-28

Last Posted Date: 2025-05-06

Lead Sponsor: Alumis Inc

Target Recruit Count: 388

Registration Number: NCT05966480

Locations: 🇧🇬
Investigator Site #5521, Plovdiv, Bulgaria
🇧🇬
Investigator Site #5529, Ruse, Bulgaria
🇧🇬
Investigator Site #5522, Sofia, Bulgaria

and more 172 locations

POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU

Phase 2

Terminated

Conditions: Noninfectious Panuveitis
Uveitis Posterior Non-Infectious
Uveitis, Intermediate

Interventions: Drug: ESK-001

First Posted Date: 2023-07-20

Last Posted Date: 2024-08-28

Lead Sponsor: Alumis Inc

Target Recruit Count: 36

Registration Number: NCT05953688

Locations: 🇺🇸
Investigator Site #1076, Palisades Park, New Jersey, United States
🇺🇸
Investigator Site #1064, Erie, Pennsylvania, United States
🇺🇸
Investigator Site #1073, Los Angeles, California, United States

and more 14 locations

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Phase 2

Active, not recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: ESK-001

First Posted Date: 2023-02-22

Last Posted Date: 2025-02-17

Lead Sponsor: Alumis Inc

Target Recruit Count: 165

Registration Number: NCT05739435

Locations: 🇺🇸
Investigator Site #1018, Los Angeles, California, United States
🇺🇸
Investigator Site #1035, Macon, Georgia, United States
🇺🇸
Investigator Site #1017, Owensboro, Kentucky, United States

and more 35 locations

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: ESK-001
Drug: Placebo

First Posted Date: 2022-10-31

Last Posted Date: 2024-07-23

Lead Sponsor: Alumis Inc

Target Recruit Count: 228

Registration Number: NCT05600036

Locations: 🇺🇸
Investigator Site #1035, Macon, Georgia, United States
🇺🇸
Investigator Site #1017, Owensboro, Kentucky, United States
🇺🇸
Investigator Site #1031, New Brighton, Minnesota, United States

and more 50 locations

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: ESK-001
Drug: Rabeprazole

First Posted Date: 2022-04-15

Last Posted Date: 2023-05-09

Lead Sponsor: Alumis Inc

Target Recruit Count: 14

Registration Number: NCT05330858

Locations: 🇺🇸
Alumis Central Site, Glendale, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy